SecProbe.io

CORRESP
1
filename1.htm

EyeGate Pharmaceuticals, Inc.

271 Waverley Oaks Road, Suite 108

Waltham, Massachusetts 02452

June 6, 2017

VIA EDGAR

United States Securities and Exchange
Commission
 Division of Corporation Finance
 100 F. Street, N.E.
 Washington, D.C. 20549

 Re: EyeGate Pharmaceuticals, Inc. (the “Company”)

Registration Statement on Form S-1

File No. 333-217418

Request
for Acceleration

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities
Act of 1933, as amended, the Company respectfully requests acceleration by the Securities and Exchange Commission (the “Commission”)
of the effective date of the Registration Statement on Form S-1 (File No. 333-217418) (the “Registration Statement”)
of the Company. The Company respectfully requests that the Registration Statement become effective as of 5:00 p.m., Washington,
D.C. time, on June 8, 2017, or as soon as practicable thereafter.

The Company respectfully requests that it
be notified of such effectiveness by a telephone call to Robert A. Petitt of Burns & Levinson LLP at (617) 345-3361 and that
such effectiveness also be confirmed in writing.

If you have any further questions or comments,
or if you require any additional information, please contact the undersigned by telephone at (781) 788-9043 or our attorney, Robert
A. Petitt at the number above. Thank you for your assistance.

    Very truly yours,

    EyeGate Pharmaceuticals, Inc.

    By:
    /s/ Stephen From

    Name:
    Stephen From

    Title:
    President and Chief Executive Officer

 cc: Robert A. Petitt, Esq., Burns & Levinson LLP